In this month's issue of Biology of Reproduction, an article by Salvetti et al. [1] describes the effects of prenatal androgen exposure on ovarian follicular characteristics throughout the fetal, prepubertal, and postpubertal ovarian lifespan. Over time, the striking differences induced by this endocrine insult are 1) androgen dependent, 2) likely estrogen dependent, 3) developmental stage dependent, and 4) follicular stage dependent. Moreover, Salvetti et al. [1] identified several developmental differences in agents that provide for follicular cell proliferation, survival, and death, thereby potentially altering follicular lifespan.
The authors have made use of an animal model that has served well for decades at the University of Michigan: sheep exposed to androgens between Days 30 and 90 days of fetal development during the ;147-day gestation. This model has been used to identify numerous androgen-dependent and perhaps estrogen-dependent actions when administered during the fetal period and has led to a better understanding of several key neuroendocrinological and phenotypical developmental differences between males and females [2, 3] . More recently, Dr. Padmanabhan and colleagues have used this model to approach several questions related to neuroendocrine regulation [4] , insulin resistance and sensitivity [5] , fetal growth [6] , testicular defects [7] , ovarian defects [8] , and follicular persistence [9, 10] . In the present study, they tested the hypothesis that exposure to excess prenatal androgens would alter the delicate balance between intraovarian proliferative, antiapoptotic, and proapoptotic regulators in a developmentspecific manner. As is a hallmark of this type of study, they also included prenatal treatment with a nonaromatizable androgen, dihydrotestosterone, to tease out those components that may be affected by an androgen versus those that may be responsive to an estrogen. Ovaries of exposed ewes were evaluated prenatally, prepubertally, and postpubertally for two breeding seasons-well into adulthood. Markers evaluated included those for proliferative activity (proliferating cell nuclear antigen), proapoptotic proteins (BAX, CASP3, FAS, FASLG), and antiapoptotic proteins (BCL2). The quantity and patterns of these markers were evaluated in ovarian sections through the developmental stages identified above.
The investigation demonstrated that the prenatal treatment resulted in changes in these markers in a follicle-, age-, and steroid-dependent manner. Some changes were observed only prenatally and others only postnatally, indicating a clear developmental distinction and perhaps an influence by hormones of the dam versus hormonal regulation within the postnatal animal. The prenatal alterations appeared to be the result of androgenic actions, while the postnatal alterations seemed more likely the result of estrogenic actions. One of the parameters measured (FAS expression) was unaffected by any treatment, indicating specificity of the observations. Clearly, the trajectory of the expression of these follicular modulators was altered by the prenatal androgen treatment and ultimately resulted in the differential regulation of these parameters well into adulthood.
The implications of this research are far reaching and touch on numerous areas of interest to reproductive biologists as well as to clinicians. Given that this treatment has shown effects of insulin resistance and sensitivity as well as deviations from normal follicular proliferation and apoptosis, this model system may provide relevant data for polycystic ovary syndrome. In addition, this model system can provide information relative to alterations in follicle turnover and/or follicle recruitment important for reproductive longevity in both animals and humans. Finally, the model system is valuable as a tool for investigating the general aspects of the toxicology of prenatal exposure to endocrine agents and/or endocrine disruptors with resulting alterations in the adult animal. The inclusion of the nonaromatizable androgen dihydrotestosterone serves to help isolate those alterations restricted to androgen exposure from those that may be the result of estrogen exposure.
